2022 Fiscal Year Final Research Report
Development of control method of immune response after multiple islet transplantation in anticipation of ES/iPS cell transplantation
| Project/Area Number |
20K08999
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Aichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 膵島移植 / 免疫制御 / 間葉系幹細胞 |
|---|
| Outline of Final Research Achievements |
To improve islet transplantation outcomes, we have begun developing immunoregulatory protocols using Stem cells from human exfoliated deciduous teeth (SHED), which have higher functional characteristics among Mesenchymal stem cells (MSC).
Unlike MSCs, which are easily affected by the cell culture environment, we have confirmed that SHEDs are a stable cell population. The ability to produce inhibitory factors was also significantly enhanced in SHED. Furthermore, we confirmed that SHED strongly suppressed human PBMC activation and cytotoxic activity to pancreatic islets. We confirmed that the PD1-PDL1 pathway is involved in this effect and that the immunosuppressive effect of MSC/SHD is not only mediated by humoral factors but also by cell-cell contact mechanisms.
|
| Free Research Field |
移植免疫
|
| Academic Significance and Societal Importance of the Research Achievements |
1型糖尿病に対する根治的治療法として死体ドナーからの同種膵島移植だけでなく、異種膵島やES/iPS細胞を用いた膵島移植にも期待がかかっている。しかしながら、移植医療普及のためには細胞移植治療効率を上げるための工夫が必要不可欠となる。免疫抑制効果を有するMSC/SHEDを用いることで膵島グラフト傷害が回避できる可能性について研究した。
本研究の結果、限られたグラフト提供を有効に活用するための治療戦略を開発することで、移植成績の向上、患者のQuality of life の改善、2型糖尿病への応用など臨床面だけでなく、医療費削減など経済面においても貢献ができると考える。
|
